Kura Oncology outlines targeted cancer pipeline as investors watch clinical milestones
Kura Oncology Inc. is a biotech company focused on developing targeted therapies for difficult-to-treat cancers. The company's strategy involves advancing small-molecule drugs through clinical trials for genetically defined cancer subsets, a common approach in the US oncology sector. Investors are closely monitoring clinical milestones and potential partnerships, with their interest driven by the company's precision medicine approach and diversified pipeline.
Kura Oncology offers stock options to five new hires
Kura Oncology announced the grant of nonstatutory stock options for 68,750 shares to five new employees on July 1, 2026, with an exercise price of $10.78 per share. These inducement grants are made under the company's 2023 Inducement Option Plan, as amended, and align with Nasdaq Listing Rule 5635(c)(4). The options will vest over four years, with an initial 25% vesting after one year, followed by monthly vesting over the next 36 months, contingent on continued employment.
Kura Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Kura Oncology, Inc. announced that its Compensation Committee granted inducement awards to five new employees. These awards consist of nonstatutory stock options to purchase 68,750 shares of common stock, with an exercise price of $10.78 per share, vesting over four years. This action aligns with Nasdaq Listing Rule 5635(c)(4) as an inducement material to their employment.
Kura Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Kura Oncology, Inc. announced that its Compensation Committee granted inducement awards consisting of nonstatutory stock options to five new employees. These options, totaling 68,750 shares of common stock with an exercise price of $10.78 per share, were approved as a material inducement for employment under Nasdaq Listing Rule 5635(c)(4). The grants vest over four years, subject to continued service.
Kura Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Kura Oncology, Inc. announced that its Compensation Committee granted inducement awards consisting of nonstatutory stock options for 68,750 shares to five new employees on July 1, 2026. These awards, made under the Company's 2023 Inducement Option Plan, are a material inducement for employment in accordance with Nasdaq Listing Rule 5635(c)(4). The stock options have an exercise price of $10.78 per share and will vest over four years.
Kura Oncology Reports Q1 2026 Results: Full Earnings Call Transcript
Kura Oncology reported Q1 2026 net product revenue of $5.8 million for Comzifty, exceeding expectations in its first full quarter since commercial launch. The company emphasizes expanding Comzifty's use across the AML treatment spectrum, including combination therapies, and anticipates significant data readouts over the next 12-24 months.
Kura Oncology, Inc.(NasdaqGS:KURA) added to Russell Small Cap Comp Growth Benchmark
Kura Oncology, Inc. (NasdaqGS:KURA) has been added to the Russell Small Cap Comp Growth Benchmark, along with the Russell 2500 Growth and Russell 3000E Growth Benchmarks. The biopharmaceutical company, focused on precision medicine for cancer treatment, was also dropped from the Russell Small Cap Comp Value and Russell 3000 Value Benchmarks. The article highlights Kura Oncology's pipeline, including candidates like Ziftomenib, Tipifarnib, and Darlifarnib, which target cancer signaling pathways.
Kura Oncology, Inc.(NasdaqGS: KURA) added to Russell 2500 Growth Benchmark
Kura Oncology, Inc. (NasdaqGS: KURA) has been added to the Russell 2500 Growth Benchmark, as announced on June 29, 2026. This inclusion reflects the company's growth trajectory and highlights its position within the small-cap growth market. Kura Oncology is a clinical-stage biopharmaceutical company focused on precision medicine for cancer treatment, with a pipeline including KOMZIFTI (Ziftomenib), Tipifarnib, and Darlifarnib.
Kura Oncology, Inc. liabilities 2021-2025
This article from Statista presents data on the liabilities of Kura Oncology, Inc. from 2021 to 2025. The company's liabilities are reported to have continuously increased from 2021 to 2025, reaching a specific amount in 2025, according to data from their fiscal year ending December 31. The exact financial figures are hidden and require a Statista account for full access.
Kura Oncology, Inc. Actuals & Estimates (NASDAQ:KURA)
This article provides an overview of Kura Oncology, Inc. (NASDAQ: KURA) stock, including its current price, historical performance, analyst forecasts, and financial data. It highlights the company's market capitalization, upcoming earnings report, and recent financial results, such as revenue and net income.
Kura Oncology, Inc. Actuals & Estimates (DUS:KUR)
This article provides an overview of Kura Oncology, Inc. (DUS:KUR) stock, including financial data, analyst estimates, historical prices, and future earnings reports. It details the company's past earnings and revenue, current EBITDA, and confirms that it does not pay dividends.
Kura Oncology, Inc. Actuals & Estimates (HAM:KUR)
This article provides an overview of Kura Oncology, Inc. (HAM:KUR) financial data, analyst estimates, and stock performance. It includes details on revenue, earnings, EBITDA, stock forecasts, and historical price movements, alongside answers to frequently asked questions about the company's financials and stock trading.
Insiders At Kura Oncology Sold US$1.5m In Stock, Alluding To Potential Weakness
Kura Oncology (NASDAQ:KURA) saw its insiders sell US$1.5 million worth of stock over the last year, indicating a potential weakness in the company's outlook. This sell-off occurred despite a generally flat share price, with analysts expecting the company to become profitable in the future. Investors should consider if the insider selling aligns with their own assessment of the company's prospects.
Kura Oncology CMO Mollie Leoni sells $834,283 in common stock By Investing.com
Mollie Leoni, CMO of Kura Oncology, sold 84,929 shares of company stock for approximately $834,283. These shares were acquired through restricted stock units and sold under a Rule 10b5-1 trading plan. The sale follows a strong 77% return for KURA shares over the past year and comes amidst positive clinical trial updates and analyst support for the company.
Form 4 Kura Oncology Inc For: 22 June By Investing.com
This article from Investing.com reports on a Form 4 filing for Kura Oncology Inc. The filing was made on June 22nd and the article provides no further details beyond this announcement. The core content is simply the title and a repetition of the details within the body.
Form 4 Kura Oncology Inc For: 22 June By Investing.com
This article reports on a Form 4 filing for Kura Oncology Inc. as of June 22. It provides the date of the filing and indicates that the news is published by Investing.com. The information suggests a routine disclosure related to insider trading or ownership changes for the company.
Kura Oncology (NASDAQ: KURA) CMO sells 84,929 shares in trading plan
Kura Oncology's Chief Medical Officer, Mollie Leoni, sold 84,929 shares of common stock on June 18, 2026, at a weighted average price of $9.8233 per share, totaling approximately $834,283. This sale was conducted under a pre-arranged Rule 10b5-1 trading plan adopted on March 19, 2026. Following the transaction, Leoni directly holds 182,345 shares of Kura Oncology.
Understanding the Setup: (KURA) and Scalable Risk
The article provides an analysis of Kura Oncology Inc. (NASDAQ: KURA), highlighting positive near-term sentiment that may counter a mid-term weak bias within a long-term strong trend. It points out that resistance is being tested and details specific trading strategies for different risk profiles, including long and short setups with defined entry points, targets, and stop losses. The analysis is based on AI-generated signals and multi-timeframe assessments of support and resistance levels.
[144] Kura Oncology, Inc. SEC Filing
This article details a Form 144 SEC filing by Kura Oncology, Inc. for a proposed sale of securities. The filing indicates a sale of 84,929 shares of common stock with an aggregate market value of $812,770.53 through Morgan Stanley Smith Barney LLC on NASDAQ, dated June 18, 2026. The securities were acquired on January 26, 2022, as Restricted Stock Units from the Issuer.
Kura Oncology Inc (KURA) Earnings Forecast: Future EPS & Revenue Growth Estimates
Kura Oncology Inc (KURA) has an earnings forecast score of 8.25. Analysts have given KURA a strong buy rating with an average price target of $28.00, ranging from $16.00 to $76.00. The company's expected revenue for the next quarter is $20.84 million, with an expected EPS of -$0.88.
Kura Oncology Inc (KURA) Financial Health: Profitability & Balance Sheet Analysis
Kura Oncology Inc (KURA) has a weak financial status and low operating efficiency, ranking 320 out of 388 in the Biotechnology & Medical Research industry with a financial score of 5.85. Despite this, its latest quarterly revenue increased by 29.47% year-over-year to $18.27 million, and net profit saw a 27.69% year-over-year increase. The report highlights areas like cash and cash equivalents, total assets, total liabilities, and free cash flow as significant parts of its financials.
Kura Oncology Inc (KURA) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution
This article provides a revenue breakdown for Kura Oncology Inc (KURA), focusing on its business segments and regional revenue contributions. However, it states that relevant financial data for FY2024, FY2025, and specific quarters have not yet been disclosed by the company. The only specific financial detail mentioned is $67.48 million in revenue from the United States, although its proportion is listed as 0.00%.
KURA Reiterates by Citizens -- Price Target Maintained at $24.00
Citizens has reaffirmed its "Market Outperform" rating for Kura Oncology (KURA), maintaining a price target of $24.00. While analysts express confidence in the biotechnology company's potential, Kura's GF Score™ of 30 suggests challenges in financial strength and profitability. Insider activity over the past three months shows sales totaling $0.2 million.
Kura Oncology, Inc. (KURA) Presents at European Hematology Association (EHA) 2026 Congress - Slideshow
Kura Oncology, Inc. (KURA) presented a slideshow at the European Hematology Association (EHA) 2026 Congress on June 13, 2026. This presentation was published by Kura Oncology, Inc. in conjunction with the event. SA Transcripts, Seeking Alpha's transcripts team, was responsible for the development of this transcript-related content.
Kura Oncology And Kyowa Kirin Report Encouraging Long-Term Results for Ziftomenib / 7+3 Combination In Newly Diagnosed AML
Kura Oncology and Kyowa Kirin have reported encouraging long-term results from the Phase 1/2 KOMET-007 trial, evaluating ziftomenib in combination with intensive chemotherapy for newly diagnosed NPM1-m or KMT2A-r AML. The trial demonstrated high remission rates, deep molecular responses, and encouraging durability, with a 12-month overall survival rate of 94% for NPM1-m AML patients. These findings strengthen confidence in the ongoing Phase 3 KOMET-017 registrational study and suggest ziftomenib could be a transformative therapeutic approach for AML.
Kura Oncology And Kyowa Kirin Report Encouraging Long-Term Results for Ziftomenib / 7+3 Combination In Newly Diagnosed AML
Kura Oncology and Kyowa Kirin have reported encouraging long-term results from the Phase 1/2 KOMET-007 trial, evaluating ziftomenib in combination with intensive chemotherapy (7+3) for newly diagnosed NPM1-m or KMT2A-r AML. The study shows high remission rates, deep molecular responses, and encouraging durability, with a 12-month overall survival rate of 94% for NPM1-m AML patients and 71% for KMT2A-r AML patients. These findings, which compare favorably to historical standard-of-care data, strengthen confidence in the ongoing Phase 3 KOMET-017 registrational study.
Number of shareholders of Kura Oncology, Inc. – NASDAQ:KURA
This article provides details on Kura Oncology, Inc. (NASDAQ: KURA), focusing on its number of shareholders. It lists various financial data sources and tools available on the TradingView platform for analyzing the company's performance. The article does not provide the actual number of shareholders but rather the framework within which such data could be accessed.
Kura Oncology And Kyowa Kirin Report Encouraging Long-Term Results for Ziftomenib / 7+3 Combination In Newly Diagnosed AML
Kura Oncology and Kyowa Kirin announced compelling long-term results from their Phase 1/2 KOMET-007 trial. The study found high remission rates, deep molecular clearance, and encouraging durability for ziftomenib combined with intensive chemotherapy in newly diagnosed NPM1-m or KMT2A-r AML. These findings, which compare favorably to historical standard-of-care data, support the ongoing Phase 3 KOMET-017 registrational study and highlight the potential for ziftomenib to transform frontline AML treatment.
Experimental leukemia combo keeps 94% of NPM1-m patients alive at 1 year
Kura Oncology and Kyowa Kirin reported encouraging long-term Phase 1/2 KOMET-007 data for ziftomenib in combination with intensive chemotherapy (7+3) for newly diagnosed NPM1-mutant (NPM1-m) and KMT2A-rearranged (KMT2A-r) Acute Myeloid Leukemia (AML). The study showed a 12-month overall survival rate of 94% for NPM1-m patients and 71% for KMT2A-r patients, with high complete remission rates and manageable safety. These results support the ongoing Phase 3 KOMET-017 program and suggest ziftomenib could become a foundational treatment for frontline AML.
Kura Oncology And Kyowa Kirin Report Encouraging Long-Term Results for Ziftomenib / 7+3 Combination In Newly Diagnosed AML
Kura Oncology and Kyowa Kirin announced positive long-term results from the Phase 1/2 KOMET-007 trial for ziftomenib combined with 7+3 chemotherapy in newly diagnosed AML patients. The study showed high composite remission rates (90-96%), deep molecular responses, and encouraging durability with a favorable safety profile. These findings support the ongoing Phase 3 KOMET-017 registrational study and suggest ziftomenib could be a foundational treatment for frontline AML.
Kura Oncology And Kyowa Kirin Report Encouraging Long-Term Results For Ziftomenib And 7+3 Combination In Newly Diagnosed AML
Kura Oncology and Kyowa Kirin announced promising long-term results from their Phase 1/2 KOMET-007 trial, evaluating ziftomenib alongside 7+3 chemotherapy in newly diagnosed AML patients. The data presented at the European Hematology Association 2026 Congress showed high remission rates, deep molecular responses, and encouraging durability with a manageable safety profile in patients with NPM1-m or KMT2A-r AML. Ziftomenib, already FDA-approved as monotherapy for relapsed/refractory AML, is under investigation for this combination use, with full peer-reviewed publication expected in the latter half of 2026.
Kura Oncology And Kyowa Kirin Report Encouraging Long-Term Results for Ziftomenib / 7+3 Combination In Newly Diagnosed AML
Kura Oncology and Kyowa Kirin announced positive long-term results from their Phase 1/2 KOMET-007 trial for ziftomenib combined with intensive chemotherapy (7+3) in newly diagnosed NPM1-mutant or KMT2A-rearranged Acute Myeloid Leukemia (AML). The data showed high remission rates (96% CRc in NPM1-m AML, 90% in KMT2A-r AML), deep molecular responses, and encouraging durability with a favorable safety profile. These results bolster confidence in the ongoing Phase 3 KOMET-017 registrational study, indicating ziftomenib's potential as a foundational treatment in frontline AML.
Kura Oncology And Kyowa Kirin Report Encouraging Long-Term Results for Ziftomenib / 7+3 Combination In Newly Diagnosed AML
Kura Oncology and Kyowa Kirin announced encouraging long-term results from the Phase 1/2 KOMET-007 trial evaluating ziftomenib in combination with intensive chemotherapy for newly diagnosed NPM1-m or KMT2A-r AML. The data showed high remission rates, deep molecular responses, and sustained durability, with a 12-month OS rate of 94% for NPM1-m AML and 71% for KMT2A-r AML patients. These findings support the ongoing Phase 3 KOMET-017 registrational study and suggest ziftomenib could be a transformative therapeutic approach, potentially reducing the need for allogeneic hematopoietic cell transplantation.
Kura Oncology (Nasdaq:KURA) - Stock Analysis
Kura Oncology (KURA) is a clinical-stage biopharmaceutical company focused on cancer treatments. The company's stock is currently trading at US$8.81, with analysts having a consensus target of US$31.17, suggesting it is significantly undervalued. Recent news highlights include positive clinical data for its drugs darlifarnib and ziftomenib, and the FDA approval of ziftomenib (KOMZIFTI) for NPM1-mutated AML.
Kura Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Kura Oncology, Inc. announced that its Compensation Committee granted inducement awards consisting of nonstatutory stock options to purchase 53,000 shares of common stock to four new employees. These awards, approved under Nasdaq Listing Rule 5635(c)(4), have an exercise price of $9.04 per share and will vest over four years, subject to continued employment. The grants are intended to incentivize the new employees in accordance with the company's 2023 Inducement Option Plan.
Kura Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Kura Oncology, Inc. announced the grant of inducement stock options to four new employees on June 1, 2026, under Nasdaq Listing Rule 5635(c)(4). These awards consist of nonstatutory stock options to purchase 53,000 shares of common stock, with an exercise price of $9.04 per share, vesting over four years. This action is intended to incentivize new hires and aligns with the company's commitment to precision medicines for cancer treatment.
[8-K] Kura Oncology, Inc. Reports Material Event
Kura Oncology, Inc. filed an 8-K report detailing the results of its Annual Meeting of Stockholders held on June 4, 2026. Key approvals included expanding the 2014 Equity Incentive Plan by 6.5 million shares and the 2015 Employee Stock Purchase Plan by 2.5 million shares. Stockholders also elected three Class III directors, ratified Ernst & Young LLP as the independent auditor, and approved executive compensation on an advisory basis, opting for an annual say-on-pay vote.
UBS Maintains Kura Oncology(KURA.US) With Buy Rating, Maintains Target Price $15
UBS has reiterated its Buy rating on Kura Oncology (KURA.US) and maintained its price target of $15. This indicates a continued positive outlook from the financial institution regarding the company's stock performance and valuation.
Kura Oncology (KURA) director receives 35,000 options at $8.77 strike price
Kura Oncology director Helen Louise Collins was granted 35,000 stock options at an exercise price of $8.77 per share. These options vest in full on the one-year anniversary of the grant date and will expire on June 3, 2036. Following this grant, she directly holds options covering 35,000 shares, increasing her potential equity stake in the company.
Kura Oncology (KURA) director receives grant of 35,000 stock options at $8.77
Kura Oncology director Michael Vasconcelles was granted 35,000 stock options with an exercise price of $8.77 per share, vesting in full one year from the grant date and expiring on June 3, 2036. This transaction is categorized as a compensation-related grant rather than an open-market trade. The Form 4 filing details the grant size, exercise price, and post-transaction holdings, confirming Vasconcelles now directly holds options for 35,000 shares.
Director at Kura Oncology (NASDAQ: KURA) receives 35,000-share option grant
Kura Oncology's director, Diane L. Parks, was granted an option to purchase 35,000 shares of common stock at an exercise price of $8.77 per share. The option, which vests in full on the one-year anniversary of the grant date, expires on June 3, 2036. This transaction was reported via a Form 4 SEC filing and is categorized as a compensation-related award rather than an open-market purchase or sale.
Director Mary Szela awarded 35,000 Kura Oncology (KURA) options
Kura Oncology director Mary T. Szela was granted 35,000 stock options with an exercise price of $8.77 per share, as detailed in a recent SEC Form 4 filing. These options will vest in full on the one-year anniversary of the grant date and are set to expire on June 3, 2036. This award increases her direct holdings to 35,000 options, reflecting a compensation-related acquisition rather than an open-market transaction.
Kura Oncology (KURA) awards director stock options at $8.77 strike
Kura Oncology director Faheem Hasnain was granted 35,000 stock options with an exercise price of $8.77 per share, as detailed in a recent Form 4 filing. These options, which vest in full on the one-year anniversary of the grant date, expire on June 3, 2036, and represent a standard equity compensation award rather than an open-market purchase. This transaction increases Hasnain's option holdings to 35,000 shares.
A Quick Look at Today's Ratings for Kura Oncology(KURA.US), With a Forecast Between $28 to $40
This article provides an overview of recent analyst ratings for Kura Oncology (KURA.US), highlighting a future price target range of $28 to $40. The piece would typically detail the sentiment and specific recommendations from various financial analysts.
Cantor Fitzgerald reiterates Kura Oncology stock Overweight rating
Cantor Fitzgerald has reiterated an Overweight rating on Kura Oncology (NASDAQ:KURA), highlighting the biotech company's pipeline advancements with darlifarnib and its potential in KRAS-mutant cancers. Despite a recent stock decline, analysts maintain a strong buy consensus, viewing the stock as undervalued. Kura Oncology also presented positive Phase 1a data for darlifarnib in combination with adagrasib for various cancers, reinforcing its development strategy.
Cantor Fitzgerald reiterates Kura Oncology stock Overweight rating By Investing.com
Cantor Fitzgerald reiterated an Overweight rating on Kura Oncology (NASDAQ:KURA), highlighting the company's darlifarnib presentation at ASCO as a key advancement for its pipeline. Despite a recent stock decline, analysts maintain a Strong Buy consensus, and InvestingPro analysis suggests the stock is currently undervalued. Kura Oncology also presented positive Phase 1a data for its darlifarnib and adagrasib combination in various cancers, underscoring its ongoing research in cancer treatment.
Barclays Maintains Kura Oncology(KURA.US) With Buy Rating, Maintains Target Price $28
Barclays has reiterated its Buy rating for Kura Oncology (KURA.US) and maintained its target price at $28. This reflects the firm's continued positive outlook on the company's stock.
Kura Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Kura Oncology, Inc. announced inducement awards of nonstatutory stock options to four new employees, totaling 53,000 shares of common stock. These grants, made on June 1, 2026, under the company's 2023 Inducement Option Plan, are consistent with Nasdaq Listing Rule 5635(c)(4). The options have an exercise price of $9.04 per share and will vest over four years, contingent on continued employment.
Citizens reiterates Kura Oncology stock rating on FIT-001 data
Citizens has reaffirmed its Market Outperform rating and $24.00 price target for Kura Oncology (NASDAQ:KURA) after an investor event highlighted positive data from the FIT-001 study. Despite a recent stock dip, analysts maintain a Strong Buy consensus, driven by the potential of Kura's FTI platform and a solid cash position. The company is also advancing new platform studies and expects updated ziftomenib data.
Kura Oncology Highlights Darlifarnib’s Potential as a
Kura Oncology presented new clinical and translational data at the 2026 ASCO Annual Meeting, highlighting darlifarnib as a potential foundational combination platform for KRAS-mutant cancers. Preliminary Phase 1a data from darlifarnib + adagrasib showed objective response rates of 67% in pancreatic cancer, 50% in non-small cell lung cancer, and 29% in KRAS inhibitor-naïve colorectal cancer patients. The company plans to initiate a new platform study to evaluate darlifarnib across multiple targeted therapies and disease settings, with the first combination, darlifarnib + daraxonrasib in KRAS-mutant pancreatic cancer, expected to begin Phase 1a evaluation in early 2027.
